瑞戈非尼 Regorafenib Regorafenib, also known as BAY 73-4506 ; is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities.

鲁索替尼 Ruxolitinib Also known as INC424 and INCB18424 or INCB018424, is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities.

厄达替尼 Erdafitinib Erdafitinib, also known as JNJ-42756493, is a potent and selective orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity.

米哚妥林 Midostaurin Midostaurin, also known as PKC-412, PKC-412A and CGP 41251; is a synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities.

吉列替尼 Gilteritinib Gilteritinib, also known as ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.

拉帕替尼 is a synthetic, orally-active quinazoline with potential antineoplastic activity.